Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

Table 4 Relationship between persistency index and outcome measures (mixed effects regression analysis)

	Beta coefficient^b (standard error)
Outcome(s) with adjustment^a	Intercept	Time, years	Persistency index	Persistency index × time
MMSE	3.89 (2.001)	-2.58 (0.13)^c	-1.09 (0.77)	1.02 (0.23)^c
ADAS-Cog^d	55.45 (5.65)^c	3.68 (0.66)^c	-3.75 (2.09)	2.74 (1.32)^e
BPMSE	10.46 (3.47)^e	-2.55 (0.25)^c	-1.76 (1.90)	1.00 (0.52)
PSMS	10.03 (1.85)^c	1.68 (0.12)^c	-0.09 (0.66)	-0.43 (0.21)^f
IADL	18.63 (2.54)^c	2.36 (0.17)^c	4.19 (0.91)^c	-1.42 (0.29)^c
CDR-SB	11.43 (1.43)^c	1.67 (0.09)^c	1.42 (0.54)^e	-0.61 (0.17)^g

^aAdjustment made for early exposure index, gender, education, age, pre-progression rate, and the severity of disease at baseline. ^bMean change in score associated with each variable. ^cP < 0.0001. ^dWhen the linear trend and quadratic trend change were included in the model the coefficients (standard errors) for time-squared and time-squared by persistency index interaction are 0.19 (0.14) and -0.83 (0.26)^e, respectively. ^eP < 0.01; ^fP < 0.05; ^gP < 0.001; otherwise, P = not significant, based on type 3 F test. ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; BPMSE, Baylor Profound Mental Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.

ISSN: 1758-9193